Integra LifeSciences Holdings (IART)
Debt-to-capital ratio
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long-term debt | US$ in thousands | 1,395,820 | 1,419,620 | 1,333,410 | 1,337,210 | 1,300,490 | 1,381,140 | 1,385,540 | 1,389,930 | 1,388,680 | 1,387,430 | 1,386,180 | 1,484,910 | 1,408,220 | 1,414,000 | 1,472,320 | 1,478,190 | 1,198,560 | 1,274,050 | 1,204,540 | 1,205,020 |
Total stockholders’ equity | US$ in thousands | 1,587,880 | 1,579,220 | 1,683,160 | 1,674,940 | 1,804,400 | 1,724,410 | 1,660,920 | 1,615,200 | 1,684,800 | 1,631,690 | 1,574,980 | 1,529,330 | 1,514,870 | 1,397,990 | 1,349,100 | 1,341,800 | 1,416,740 | 1,384,970 | 1,420,950 | 1,397,030 |
Debt-to-capital ratio | 0.47 | 0.47 | 0.44 | 0.44 | 0.42 | 0.44 | 0.45 | 0.46 | 0.45 | 0.46 | 0.47 | 0.49 | 0.48 | 0.50 | 0.52 | 0.52 | 0.46 | 0.48 | 0.46 | 0.46 |
December 31, 2023 calculation
Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $1,395,820K ÷ ($1,395,820K + $1,587,880K)
= 0.47
The debt-to-capital ratio of Integra Lifesciences Holdings Corp has been relatively stable over the past few quarters, ranging between 0.44 and 0.49. This ratio indicates that the company relies on debt to finance a significant portion of its capital structure, with debt representing a range of 44% to 49% of the company's total capital.
The stability of the ratio suggests that the company has been managing its debt levels consistently over time. A higher debt-to-capital ratio may indicate increased financial risk due to higher leverage, potentially leading to higher interest payments and financial difficulty in case of economic downturns. Conversely, a lower ratio indicates a lower reliance on debt financing and potentially lower financial risk.
It would be beneficial for stakeholders to monitor any changes in Integra Lifesciences Holdings Corp's debt-to-capital ratio in future quarters to assess the company's financial health and risk profile.
Peer comparison
Dec 31, 2023